SYNTHORIN
Dead / Abandoned — Abandoned — no statement of use filed (as of 31 Jan 2022)
What this means for you
This application is over — abandoned 31 Jan 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87695246
- Mark type
- Stylized text
- Filed
- 22 Nov 2017
- Published for opposition
- 30 Oct 2018
- Abandoned
- 31 Jan 2022
- Attorney of record
- Karen Lim
Goods and services
- Class 005 — Pharmaceuticals: protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases, and infectious diseases; protein therapeutics expressed, prepared or manufactured using a semi-synthetic organism, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, namely, cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, respiratory diseases, gastrointestinal diseases, cardiovascular and metabolic diseases, pathogen infections, musculoskeletal diseases, ophthalmologic and dermatologic diseases, genitourinary diseases, degenerative diseases, and orphan diseases; protein therapeutics namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from cancer and autoimmune disorders; Protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, namely, therapeutic agents in the nature of cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, coagulation factors, lipid binding proteins, anti-infectives, analgesics, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology including fertility, infectiology including virology, ophthalmology, hepatology, neurology, and geriatrics
Owner
- Synthorx, Inc., La Jolla, CA, US
- Synthorx, Inc., La Jolla, CA, US
Prosecution history
- 31 Jan 2022 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 31 Jan 2022 — ABANDONMENT - NO USE STATEMENT FILED
- 18 May 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 May 2021 — SOU EXTENSION 5 GRANTED
- 05 May 2021 — SOU EXTENSION 5 FILED
- 17 May 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 05 May 2021 — SOU TEAS EXTENSION RECEIVED
- 05 Nov 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Nov 2020 — SOU EXTENSION 4 GRANTED
- 03 Nov 2020 — SOU EXTENSION 4 FILED
- 03 Nov 2020 — SOU TEAS EXTENSION RECEIVED
- 11 Jun 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jun 2020 — SOU EXTENSION 3 GRANTED
- 09 Jun 2020 — SOU EXTENSION 3 FILED
- 09 Jun 2020 — SOU TEAS EXTENSION RECEIVED